1. Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

2. Encapsulation of Natural Polyphenolic Compounds; a Review

3. Blood-Brain Delivery Methods Using Nanotechnology.

4. Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy.

5. An updated review on modified-release tablets.

6. Polymers in pharmaceutical drug delivery system: A review

7. PCOS

It is possible to do a systematic review and meta-analysis of a comparison of clinical outcomes and relapse rates of methicillin-susceptible Staphylococcus aureus bloodstream infection between glycopeptides and beta-lactams.

In this review, the glycopeptides are being represented by vancomycin and teicoplanin; and the beta-lactams are being represented by nafcillin and cefazolin.

A major problem with this review is that there might not be any randomized controlled trials on a direct head-to-head comparison between glycopeptides and beta-lactams.

Therefore, this systematic review and meta-analysis will possibly have to be conducted on observational studies such as case-control studies, etc..

Alternatively, another topic that is worth considering is the comparative effectiveness of ceftaroline fosamil versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis.

This is because a systematic review titled "Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis" has already been published by a team of four authors in PLOS One in this year 2024.

Hence, it is possible to perform a new systematic review and meta-analysis for assessing the comparative effectiveness of ceftaroline fosamil versus vancomycin in MRSA bloodstream infections, if such a review has never been conducted before.

In the field of pharmaceutics, it is possible to do a systematic review of clinical applications of cyclodextrin nanoparticles.

This is because cyclodextrin-conjugated nanoparticles are able to combine the advantages of cyclodextrins and nanoparticles: enhanced water solubility and drug loading, targeted drug delivery with minimum toxicity to normal cells, greater surface area, improved drug loading and higher stability than other nanocarriers such as microparticles and liposomes.

The following two systematic reviews were already published in 2022 and 2021 respectively:

[1]Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review

[2]Cyclodextrin-based nanoparticles for pharmaceutical applications: A review,

Therefore, it is possible to conduct a new review on cyclodextrin nanoparticles for pharmaceutical applications as an antimicrobial agent, if such a review has never been conducted before.

The title of this new review shall be “Cyclodextrin-based nanoparticles for pharmaceutical applications as an antimicrobial agent: A review”.